NBIX - Company ID 0000914475
NEUROCRINE BIOSCIENCES INC trades as NBIX and has a market capitalization of $17.94 B, making it the #659 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.86B, up 21.4% from the prior year and net income of $478.60M. This page tracks NEUROCRINE BIOSCIENCES INC through 2,097 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years NEUROCRINE BIOSCIENCES INC's revenue grew from $15.00M to $2.86B, a compound annual growth rate of 79.2%. Net profit margin expanded from -940.6% to 16.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | Neurocrine Biosciences
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | Neurocrine Biosciences
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | Neurocrine Biosciences
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results | Neurocrine Biosciences
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 | Neurocrine Biosciences
The largest companies sharing NEUROCRINE BIOSCIENCES INC's SEC industry classification (biological products, (no diagnostic substances)).
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of $17.94 B as of 2026-07-09, ranking #659 among US-listed companies.
NEUROCRINE BIOSCIENCES INC reported revenue of $2.86B for fiscal year 2025, an increase of 21.4% year over year.
Yes. NEUROCRINE BIOSCIENCES INC reported net income of $478.60M in its latest fiscal year.